For sterile products manufacturing, Lyoseal is an innovative technology. presented by Mr. Tony Bouzerar from BioCorp offers us detailed

Similar documents
Review Validation of aseptic processes for pharmaceuticals

Aseptic Process Validation

Actavis Italy. Nerviano Plant

Why change is inevitable in aseptic manufacturing?

HISTORY AND MILESTONES

ASEPTIC TECHNOLOGIES FILLING SOLUTIONS SAFER & EASIER

Annex A2. Guidance on Process Validation Scheme for Aseptically Processed Products

Hot Topics in Drug Product Process Validation: A Reviewer s Perspective

Industry Perspective on PET Manufacturing Comparison of EU and US

PAT & Risk-Based Initiatives: Implementation Issues PDA New England - 8 th Dec Cliff Campbell B.E., C.Eng. CC&A Ltd., Cork, Ireland

Critical Environment Products and Services

Container Closure Integrity Tests (CCIT) for Single-Use Systems

Primary Packaging change: Switch from a lyophilisate in vial to a lyophilisate in double chamber cartridge

Solutions for All Your Aseptic Parenteral Drug Formulation/Filling Needs. BUBBLE-FREE FILLING : A New Option in Prefilled Syringe Filling

FlexAct BT (Bag Tester) Flexboy 2D November, 2015

Tests to Support Sterility Claim. Imtiaz Ahmed

Packaging Form Comparison:

VERISEQ NUCLEATION BETTER CONTROL OF NUCLEATION IN LYOPHILIZATION

Environmental Control Requirements. Gordon Farquharson July 2017

Vetter Development Service

Inspection Hot Topics

ISO Part 1 and Part 2 Compliance Requirements. Cathriona O Neill

ABOUT HAMELN PHARMA About us

PACKAGE TESTING AND VALIDATION SERVICES

FDA s Guidance for Industry

PACKAGE TESTING & VALIDATION IN THIS SECTION EXPERT SOLUTIONS FOR PRODUCT DEVELOPMENT

G.F. S.p.A. Via T. Edison, Rubbiano fraz. Solignano (PR) - Italy Tel Fax Web:

XTREMA HIGH SPEED FILLING & STOPPERING MACHINE

ASEPTIC TRANSFER & PURE CULTURE TECHNIQUES

Isolators v. RABS: Facility Design Considerations for a Fill-Finish Finish Suite

Guidance. Media Fills for Validation of Aseptic Preparations for Positron Emission Tomography (PET) Drugs DRAFT GUIDANCE

SCHOTT Pharmaceutical Packaging. Dedicated to quality pharmaceutical packaging

MicroFunnel Filter Funnels

Automatic inspection for vials, ampules and cartridges

Media Fill A Process Simution. Presented By Shikha Chauhan

GLOBAL QUALITY SOLUTIONS PACKAGE INTEGRITY SEAL INTEGRITY LEAK DETECTION

2-2 Sterile Product Assessment. Satish Mallya Ph.D Training Workshop CPH, May 2015

The Opta SFT-D is available as individual device for end-user assembly with TPE tubing and autoclave sterilization.

ISPE Nordic, Denmark Yves Scholler SKAN AG

Contents. Contents (13) 1 Production (23)

Technical Report No. 61 Steam In Place

Prequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer

ebro Validation-Set for large Steam Sterilizers SL 2100 The Set contains:

TRANSFER OF BACTERIA USING ASEPTIC TECHNIQUE

SCHOTT Vials. Perfection in Every Detail

Equipment Design Consideration for Cleaning & Cleaning Validation

ISPE Aseptic Conference February 2014 Washington, D.C.

Good Manufacturing Practices Purpose and Principles of GMP. Tony Gould

Particulate Matter and Visual Inspection: Industry Trends 2015

On behalf of the PHSS Pharmaceutical and Healthcare Sciences Society (UK).

Reference Standards for Monoclonal Antibodies: Key Challenges Addressed

Guiding Principles for the implementation of fluid management technologies for modern single use aseptic processing

Isolator Technology TRUKING TECHNOLOGY LIMITED

Managing Aseptic Interventions

Omron meets Pharma Milan, January 29 th Container Closure Integrity Testing (CCIT): a Risk Management Application

Calibration, Qualification and Preventive Maintenance Services Overview

Advancements on implementation of single use technology in vaccine manufacturing

Case study 2: Parenteral Drug Product

Parenteral Vial Sealing and Integrity

Vetter Development Service

Preparing Your Aseptic Processing Facility for an FDA Inspection. Valerie Welter, Director Quality Bayer HealthCare March 10, 2014

Analytical and formulation attributes

BREAK WITH TRADITION LEAK DETECTION METHODS FOR PHARMACEUTICAL BLISTER PACKS. Philip Stevenson M.Eng (Hons), Product Manager, Sepha Ltd.

Aseptic Powder Dosing Solutions

INNOVATIVE PLASTIC CONTAINERS

Novel Technologies in Plasma Fractionation. Dieter Fassnacht

Validation of Sterilizing Grade Filters

Polestar Power Industries (Pharma Division) Pioneer Manufacturer Of Beta-Lactum & Cephalosporin

G.F. S.p.A. Via T. Edison, Rubbiano fraz. Solignano (PR) - Italy Tel Fax Web:

Glossary of Freeze Drying Terms

Sterility Assurance Level and Aseptic Manufacturing Process in Pharmaceuticals

Request for Quote RFQ #

VALIDATION QUALIFICATION. Pharmaceutical Consultancy Services, All rights reserved. 1. JaapKoster

Process Filtration From Pure to Sterile

A Journey in Global PUPSIT Implementation with Benchmarking. PDA Midwest Event Oct 5th, 2017 Jeff Gaerke P.E.

for IND and RDRC Regulated PET Compounding

Guidelines for Process Validation of Pharmaceutical Dosage Forms

Flexboy 2D Pre-designed Solutions for Storage Best Performance, Assurance of Supply and Closure Integrity for All Process Steps

Second Edition. New York London

Certification, Testing, Approval and R&D work on the Absorber Safety

Annex 1 to the Good manufacturing practices guide Manufacture of sterile drugs GUI-0119

Product Questionnaire

Whitepaper. High temperature HEPA filtration. Dr.-Ing. Marc Schmidt, Dr.-Ing. Lothar Gail, Hugo Hemel MSc. Preview

Emcure Pharmaceuticals Limited 3/3/16

Packaging of Biotech Drug Products: Challenges and Innovative Solutions. Annalisa Delnevo Research Pharma Odra Pinato SG Lab Analytics

arrier Isolation Technology

Microbiology Research Associates

October 10, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852

NO 2 Gas Sterilization and Decontamination: Keeping Pace, from Start to Finish

BSL3 and BSL4 Autoclaves. Laboratory Line

Update to the Manufacturing Principles for Medicinal Products

Dimensional Stability of a Multicavity Injection Molded Article

Totally Integrated Solutions for Pharmaceutical Industry

USP Chapter 823 USP 32 (old) vs. USP 35 (new)

Gx Syringe Systems.

PART II OF II: IMPROVED PARENTERAL CONTAINERS THROUGH PLASMA DEPOSITION OF HIGH PURITY GLASS

Plastic Storage Bottles Product Selection Guide

Current Trends in Sterile Manufacturing. by Sterling Kline, RA Director of Project Development Integrated Project Services (IPS)

Meeting the challenges of medical device packaging

Single-Use Final Fill: Benefits and Considerations

Transcription:

For sterile products manufacturing, Lyoseal is an innovative technology to improve quality problems with final drug product due to crimping issues and inadequate stopper seating. It eliminates aluminum particles from process, meets more stringent requirements for capping process according to cgmp expectations. Lyoseal: Introducing a New Capping Solution for Freeze Dried Products presented by Mr. Tony Bouzerar from BioCorp offers us detailed introduction on Lyoseal from technology, process, application and validation. It offers us an alternative capping solution for freeze dried products.

PDA: A Global Lyoseal :Introducing a New Capping Solution for Freeze Association Dried Products Speaker: Tony Bouzerar, LyoSeal Customer Support Manager, BioCorp PDA Conference: Stoppers & Elastomers, Rennes, 6 th & 7 th April 2011

Purpose presentation: Lyoseal

Agenda 1. Introduction: market drivers 2. Technical Challenge: 1. how to crimp a large population of vials in one single operation? 2. The solution: LyoSeal 3. Lyoseal description 4. Case study: 1. Implementation at a customer: Modification of the manufacturing process 2. Process validation 3. Container Closure Integrity 5. Conclusion 3

Introduction: Market Drivers When speaking about sterile products manufacturing, issues are: Quality problems with final drug product due to crimping issues and inadequate stopper seating Lack of sterility Loss of vacuum in vial Cracked glass vials Cosmetic defects Stoppers sticking to Lyo chamber shelves Elimination of aluminium particles from process More stringent requirements for capping process according to EU GMP Annex 1

Introduction: Market drivers Options to meet GMP Annex 1 Option Example of Product Offering Crimping in Class 5 environment Integration of crimping process into RABS/ Isolator Capping in Freeze Dryer West Flip-Off CCS/ Clean Seals West Flip-Off CCS/ Clean Seals LyoSeal In-Line Oxygen head-space inspection on finished product Several In-line control Systems 5

Introduction: Market drivers Options to meet GMP Annex 1 + elimination of aluminium Option Example of Product Offering Capping in Freeze Dryer LyoSeal 6

Agenda 1. Introduction 2. Technical Challenge: 1. how to crimp a large population of vials in one single operation? 2. The solution: LyoSeal 3. Lyoseal description 4. Case study: 1. Implementation at a customer: Modification of the manufacturing process 2. Process validation 3. Container Closure Integrity 5. Conclusion 7

2: Technical Challenge The Challenge: How to crimp a large population of vials in a freeze-dryer? Main Issues: Pressing force from the FD machine versus crimping force needed for x vials Tolerances of the freeze-dryer shelves flatness Stacking tolerances of vials and stoppers 8

2: Technical Challenge Compression curve of a typical 20mm lyo stopper, in down position (equipment used: Lloyd; stoppers from main suppliers) 2 dan for a 0,5mm Compression For more details, please contact info@lyoseal.com or Dial +33 47355 7050 9

2: Technical Challenge Compression curve of a 20mm LyoSeal, in down position (measurement equipment used: Lloyd) For more details, please contact info@lyoseal.com or Dial +33 47355 7050 10

2: Technical Challenge Assuming a Normal Distribution of dimensions of1800 vial and stoppers on a single shelf in a Freeze-Dryer machine =1,5mm µ+ σ µ+ 2σ Shortest Highest µ+ 3σ Stopper Compression (mm) % population 0,5% 2% 13,5% 34% 34% 13,5% 2% 0,5% For more details, please contact info@lyoseal.com or dial+33 47355 7050 0,5 0,75 1 1,25 1,5 1,75 2 0.5 2 13.5 34 34 13.5 2 0.5 N vials 9 36 243 612 612 243 36 9 Compressi on (N) F 20 20<F<30 30<F<58 58<F<100 100<F<145 145<F<195 195<F<250 F 250 Total theorical cumulated vertical force transfered on stoppers =186660N or equ 18,7T 11

2: Technical Challenge Assuming a Normal Distribution of dimensions of1800 vial and stoppers on a single shelf in a Freeze-Dryer machine µ+ σ =2mm µ+ 2σ Shortest Highest µ+ 3σ Stopper compression (mm) 0,5% 2% 13,5% 34% 34% 13,5% 2% 0,5% For more details, please contact info@lyoseal.com or dial +33 47355 7050 0,5 0,8 1,2 1,5 1,8 2,15 2,5 % population 0.5 2 13.5 34 34 13.5 2 0.5 N vials 9 36 243 612 612 243 36 9 Compression (N) F 20 20<F< 35 35<F<90 90<F<145 145<F<202 202<F<285 285<F<385 F 385 Total theorical cumulated vertical force transfered on stoppers =269,145N or equ.26,9t 12

2: Technical Challenge =1,5mm µ+ σ Shortest µ+ 2σ Highest µ+ 3σ 0,5% 2% 13,5% 34% 34% 13,5% 2% 0,5% Compression Lyoseal (mm) 0 0,25 0,5 0,75 1 1,25 1,5 % population 0.5 2 13.5 34 34 13.5 2 0.5 N vials 9 36 243 612 612 243 36 9 Compression on LYOSEAL (N) For more details, please contact info@lyoseal.com or dial +33 47355 7050 F = 80 F = 75 F = 84 F = 97 F = 121 F = 77 F = 75 F = 95 Total theorical cumulated vertical force transfered on LYOSEAL =179 514 N or equ.18 T 13

2: Technical Challenge =2mm µ+ σ Shortest µ+ 2σ Highest µ+ 3σ 0,5% 2% 13,5% 34% 34% 13,5% 2% 0,5% Compression Lyoseal 0 0,3 0,6 1 1,3 1,6 5 2 For more details, please contact info@lyoseal.com or dial +33 47355 7050 % population 0.5 2 13.5 34 34 13.5 2 0.5 N vials 9 36 243 612 612 243 36 9 Compression on LYOSEAL (N) F = 80 F = 75 F = 90,4 F = 121,5 F = 74,5 F = 86,6 F = 124,8 F = 147,3 Total theorical cumulated vertical force transfered to LYOSEAL =172201N or 17,2T 14

2: Technical Challenge: summary Compression of 0,5mm of 1800units of typical rubber lyo stoppers on top of vial: average 82kN Compression of 0,5mm of 1800 crimped vials with LyoSeal: Estimated extra force needed= 0N! Conclusion: LyoSeal may compensate a moderate dispersion of dimensions including stopper dimensions, and allow a 100% crimping 15

2: Technical Challenge: facts Compatibility trials with some Freeze-Dryers from the market and capping force used: =Most FD can be used as they are. LYOSEAL 20mm Surface Area (m 2 ) Capping Pressure (kg/cm 2 ) Crimpin g Yield GEA Lyofill 2 Nominal 100% Klee Pilot scale Nominal 100% Heraus 20 Nominal 100% GEA Lyofill 20 0.7 99.73% Steris 35 1.4 99.5% Telstar 45 1.2 100% 16

Agenda 1. Introduction 2. Technical Challenge: 1. how to crimp a large population of vials in one single operation? 2. The solution: LyoSeal 3. Lyoseal description 4. Case study: 1. Implementation at a customer: Modification of the manufacturing process 2. Process validation 3. Container Closure Integrity 5. Conclusion 17

Lyoseal 20 mm Overseal Insert Flange LyoSeal is currently available in 13mm, 20mm, 28mm 18

Manufacturing in ISO 7 Ready-to- Autoclave LyoSeal are supplied in Ready-to-Autoclave PE/Tyvek bags.

Process Freeze dryer Freeze Dry & Crimp-Seal H 2 O H 2 O H 2 O 20

Agenda 1. Introduction 2. Technical Challenge: 1. how to crimp a large population of vials in one single operation? 2. The solution: LyoSeal 3. Lyoseal description 4. Case study: 1. Implementation at a customer: Modification of the manufacturing process 2. Process validation 3. Container Closure Integrity 5. Conclusion 21

Case Study: Implementation of LyoSeal version 20mm Location: Big Pharma site, Europe Purpose: Clinical Production LyoSeal version considered: 20mm 22

Drug product production process Product (Warehouse) Compounding Vessel Sterile Filtration Holding Vessel Unloading Lyo via Isolator Transfer via Isolator Lyophilisation Lyophiliser Loading Lyo via Isolator Transfer via Isolator Filling Filling Line Immediate Container (Warehouse) Rinsing Washing Machine Depyrogenation Dry Heat Oven Transfer Via Isolator 23

Modification of process equipment List of equipment: Vial filling line and isolator Pick and place system Lyoseal bowl Connection to transfer isolator New Transfer isolator New Interface isolator New standard freeze dryer 24

Modification of process equipment 25

Lyoseal deposition (movie) 26

Modification of process equipment Transfer to isolator 27

Modification of process equipment Transfer Isolator Interface Isolator (to FD pizza-door ) 28

Modification of process equipment Freeze-Dryer Tray loading of vials into FD 29

Modification of process equipment Manufacturing equipment qualification IOQ of vial filling line modifications Incl smooth operation (incl Lyoseal placement without stopper displacement) for 30 minutes IOQ, CD, PQ of new isolators Commisioning, IOQ freeze dryer Crimping force Full load crimping All vials closed, no broken vials 30

Manufacturing process simulation Initially 3 consecutive runs 3 X 1500 vials with stopper and lyoseal No growth Growth promotion capability tests passed Particle measurement during capping: class A All vials closed in lyo No vials broken in lyo Semi-annual repitition with 1500 vials 31

Container closure integrity Validation strategy: FMEA Mold qualification Dimensional check & influence of steam sterilisations Helium leak tests at t0 Microbial ingress testing: P.diminuta + E.coli Stability - after stress conditions: vacuum decay tests 32

Influence of steam sterilisations After 1 steam sterilisation & drying cycle: Changed dimensions after 1 cycle (within supplier specifications) Between 1st and 2nd steam sterilisation cycle: no changed dimension observed Similar tests at Biocorp: incl crimping force 33

Helium test: Method Material: 10, 20 and 50 ml lyophilized vials containing placebo were manufactured (GMP conditions). Method: Bottomless vials are placed into the chamber. Vacuum is set up into the chamber at approximatly 10-3 mbars. Constant 0.2 bars Helium pressure is applied into the vials. Helium leak is measured at room temperature (21 ±3C ) through a mass spectrophotometer 34

Helium test: equipment Pressure Sensor Sealing System Helium Concentration over 99% Volume 1 Valve Mass Spectrophotometer Valve Vial Chamber Flow valve 35

Helium test:results: The leak rates results are similar to the leak rates observed for vials crimped with aluminium caps. The leak rates measured correspond approximately to a The leak rates corespond approximately to a capillary channel of 0.075 µm 36

Microbial ingress test Method: 221 vials were filled with 10 ml trypticase soya broth (TSB) under media fill conditions, then immersed for 24 hours at 35 C ±2 in a contaminated media containing at least 15.10 10 Pseudomonas diminuta and 32.10 10 Escherichia coli. The vials were incubated for 14 days at 35 C ±2 and checked for microbial ingress. Growth promoting properties were tested to validate the test conditions. Results: No growth was observed in the vials from microbial ingress test. Growt promoting capability tests passed. 37

Stability study Vacuum decay test to demonstrate that the LyoSeal cap is able to maintain the integrity of finished vials product under accelerated and over the shelf life ICH storage conditions Test conditions: +5 C ±3 +25 C ±2-60% RH ±5% -20 C ±5 Equipment: +40 C ±2-75% RH ±5% Wilco (W07MC/V n 0800 52) Tester calibrated for a 20µm leak detection 38

Stability study: results 1/3 T0 T3 T6 T12 T24 T37 ICH studies : Products stored at + 5 C ±3 10 ml Lyoseal - 23/24 accepted (1) 24/24 accepted 23/24 accepted (1) 23/24 accepted (1) 10 ml Flip-off - 24/24 accepted 24/24 accepted 24/24 accepted 24/24 accepted 20 ml Lyoseal - 24/24 accepted 24/24 accepted 24/24 accepted 24/24 accepted 20 ml Flip-off - 24/24 accepted 24/24 accepted 24/24 accepted 24/24 accepted 50 ml Lyoseal - 24/24 accepted 24/24 accepted 24/24 accepted 24/24 accepted 50 ml Flip off - 24/24 accepted 23/24accepted 24/24 accepted 24/24 accepted (1): 1 broken vial not tested 39

Stability study: results 2/3 T0 T3 T6 T12 T24 T37 ICH studies : Products stored at + 25 C ±2 60% RH ±5% 10 ml Lyoseal 30/30 Accepted - - - - 10 ml Flip-off 29/30 accepted (2) - - - - 20 ml Lyoseal 30/30 Accepted 24/24 Accepted 24/24 Accepted 24/24 Accepted 24/24 Accepted 20 ml Flip-off 30/30 Accepted 24/24 Accepted 24/24 Accepted 24/24 Accepted 24/24 Accepted 50 ml Lyoseal 40/40 Accepted 24/24 Accepted 24/24 Accepted 24/24 Accepted 24/24 Accepted 50 ml Flip off 40/40 Accepted 24/24 Accepted 25/25 Accepted 23/24 Accepted 24/24 Accepted (2): Important leak detected (crimping failure) 40

Stability study: results 3/3 T0 T3 T6 T12 T24 T37 ICH accelerated studies : Products stored at -20 C ±5 C 10 ml Lyoseal - 30/30 accepted 30/30 accepted 10 ml Flip-off - 30/30 accepted 30/30 accepted 50 ml Lyoseal NA NA NA NA NA NA 30/30 accepted NA NA 50 ml Flip-off 30/30 accepted NA NA ICH accelerated studies : Products stored at 40 C ±2-75% RH ±5% 10 ml Lyoseal - 30/30 accepted 29/30 accepted 10 ml Flip-off - 30/30 accepted 30/30 accepted 20 ml Lyoseal - 30/30 accepted 30/30 accepted 20 ml Flip-off - 30/30 accepted 30/30 accepted NA NA NA NA NA NA NA NA NA NA NA NA 41

Agenda 1. Introduction 2. Technical Challenge: 1. how to crimp a large population of vials in one single operation? 2. The solution: LyoSeal 3. Lyoseal description 4. Case study: 1. Implementation at a customer: Modification of the manufacturing process 2. Process validation 3. Container Closure Integrity 5. Conclusion 42

5: Conclusion Benefits by using Lyoseal : Class A crimping Vials sealed in freeze-dryer without extra aseptic manipulation or aseptic transfer increased assurance of sterility maintenance Containment Less breakage of vials No stoppers sticking to shelves Overseal buffers closing force Elimination of crimping issues Elimination of metal components and potential metal particles =Lyoseal delivers Quality by Design 43

Outlook 2011-2012 Lyoseal distribution: IP owned by Biocorp Exclusive and worldwide Sales & Marketing licensee: West Pharmaceutical Services New production equipment using LyoSeal to be implemented in 2011 at a pharmaceutical company: Intended for Commercial production Hi-speed filling & capping Open-door day & workshop around technology being organized: Location: Europe Focus: Hi-speed filling& stoppering machine using LyoSeal in operation When: Q4/2011 If you are interested and would like to participate, please contact +33 47355 7050 or info@lyoseal.com, mentioning Lyoseal Workshop 44

Announcement Agreement 45

Thank you for your attention. Questions are welcome To get in further contact regarding Lyoseal : info@lyoseal.com +33 473 55 7050 Or your usual West Pharmaceutical Services sales contact 46